Ivermectin B1a monosaccharide

• UNSPSC Description:

  Ivermectin B1a monosaccharide is a modified Ivermectin B1a (HY-126937). Ivermectin B1a monosaccharide is an antiparasite agent with a minimum concentration for full activity in Haemonchus contortus larval development of 0.001 μg/mL[1].

• Target Antigen:

  Parasite

• Type:

  Natural Products

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/ivermectin-b1a-monosaccharide.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O[C@]1([C@@]2([H])C=C(C)[C@H]3O)[C@]3([H])OC/C1=C\C=C\[C@@H]([C@@H](/C(C)=C/C[C@]4([H])C[C@](C[C@@]5(O[C@]([C@@H](C)CC5)([H])[C@@H](C)CC)O4)([H])OC2=O)O[C@@]6([H])C[C@@H]([C@@H](O)[C@H](C)O6)OC)C

• Molecular Weight:

  730.92

• References & Citations:

  [1]Michael B,et al., Comparison of ivermectin, doramectin, selamectin, and eleven intermediates in a nematode larval development assay[J]. Journal of Parasitology, 2001, 87(3): 692-696.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  71837-27-9